Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study

Viecelli AK 1 , Pascoe EM 2 , Polkinghorne KR 3 , Hawley CM 1 , Paul-Brent PA 2 , Badve SV 2 Show all authors , Cass A 4 , Johnson DW 1 , Kerr PG 3 , Mori TA 5 , Scaria A 2 , Hooi SL 6 , Ong ML 7 , Irish AB 5 , FAVOURED Study Team

Affiliations 

  • 1 Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
  • 2 Australasian Kidney Trials Network, School of Medicine, University of Queensland, Brisbane, Queensland, Australia
  • 3 Department of Nephrology, Monash Medical Centre, Melbourne, Victoria, Australia
  • 4 Menzies School of Health Research, Charles Darwin University, Darwin, Australia
  • 5 School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
  • 6 Department of Medicine and Haemodialysis Unit, Hospital Sultanah Aminah, Johor Bahru, Malaysia
  • 7 Department of Nephrology, Penang Hospital, Georgetown, Malaysia
Nephrology (Carlton), 2016 Mar;21(3):217-28.
PMID: 26205903 DOI: 10.1111/nep.12573

Abstract

The Fish oils and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial investigated whether 3 months of omega-3 polyunsaturated fatty acids, either alone or in combination with aspirin, will effectively reduce primary access failure of de novo arteriovenous fistulae. This report presents the baseline characteristics of all study participants, examines whether study protocol amendments successfully increased recruitment of a broader and more representative haemodialysis cohort, including patients already receiving aspirin, and contrasts Malaysian participants with those from Australia, New Zealand and the United Kingdom (UK).

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications